一种新的肿瘤标志物LyGDI在卵巢癌中的表达  

A novel tumor biomark expressed in ovarian cancer

作　　者：甄红英[1] 王淑玲[1] 吴后男[1] 张小为[1] 

机构地区：[1]北京大学医学部干细胞中心,北京100191

出　　处：《中国生育健康杂志》2009年第1期6-8,11,共4页Chinese Journal of Reproductive Health

摘　　要：目的确定LyGDI是一种新的卵巢恶性肿瘤标志物。方法将受试人群分为卵巢癌、良性卵巢疾病和正常人群组,ELISA技术检测各组人群血清中LyGDI的蛋白表达水平,并通过组织免疫化学技术验证lyGDI的表达。结果血清中lyGDI水平的平均值和中位数在卵巢癌患者为3.10mg/L和2.31mg/L,明显高于良性卵巢疾病人群1.10mg/L和0.97mg/L(P<0.05)及正常人1.17mg/L和0.55mg/L(P<0.001),良性卵巢疾病和正常人群组比较,差异无统计学意义;组织化学染色,lyGDI在卵巢癌组织中高表达,在良性卵巢组织中不表达。结论lyGDI在卵巢癌中可作为一种新的肿瘤标志物。Objective To verify if lyGDI is a novel serum biomarker for ovarian carcinoma. Methods Serum lyGDI was measured by enzyme-linked immunosorbent assay for 76 healthy control, 26 patients subsequently diagnosed with ovarian cancer and 12 patients suffered from benign ovarian disease. Intracellular distribution of lyGDI was assessed by immunohistochemistry in benign and malignant ovarian disease. Results Serum lyGDI level was significantly elevated among ovarian cancer cases than among benign disease and healthy controls （P 〈 0. 001 ）. Immunohistochemical analysis demonstrated lyGDI were highly expressed in cancer cells and also found stromal lymphocytes, whereas it is only scattered in stromal lymphocytes in benign ovarian disorders. Conclusion LyGDI may display a novel biomark for screening ovarian cancer. Its distribution in tumor tissue implies it ,nay play an important role in cancinogenesis.

关 键 词：肿瘤标志物 卵巢癌 LYGDI 

分 类 号：R737.31[医药卫生—肿瘤]